William V. Bobo, MD

Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment

June 27, 2022

The aim of this study was to develop and validate a categorical definition of “no meaningful benefit” from antidepressant treatment by equating percent change in scores on 3 common...

Carl Zhang , Sanya Virani , Taryn Mayes , et al

Original Research

Urine Drug Screens and Youth Mortality

January 11, 2022

Current practices for estimating the risk for mortality in teenage substance users rely heavily on clinical intuition. This study examined whether a positive urine drug screen in youth receiving...

Matej Markota , Paul E. Croarkin , William V. Bobo

Letter to the Editor

BMI and Remission in Depressed Patients Receiving IV Ketamine

November 12, 2019

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...

Balwinder Singh , William V. Bobo , Keith G. Rasmussen , et al

Original Research

Secondary Effects of Ziprasidone Augmentation in MDD

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...

David Mischoulon , Richard C. Shelton , Lee Baer , et al

Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

January 27, 2016

Thilo Deckersbach , Andrew A. Nierenberg , Melvin G. McInnis , et al

Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

January 27, 2016

Andrew A. Nierenberg , Susan L. McElroy , Edward S. Friedman , et al

Original Research

A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

July 12, 2011

Herbert Y. Meltzer , Stefania Bonaccorso , William V. Bobo , et al

Book Review

The Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis

December 31, 2008

William V. Bobo

Original Research

Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies

May 11, 2008

Herbert Y. Meltzer , William V. Bobo , Isaac F. Nuamah , et al

Original Research

A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia

February 14, 2008

Herbert Y. Meltzer , William V. Bobo , Ajanta Roy , et al

Letter to the Editor

Potential Association Between Risperidone and Cerebrovascular Events

June 1, 2003

William V. Bobo , Kenneth F. More

Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment

Urine Drug Screens and Youth Mortality

BMI and Remission in Depressed Patients Receiving IV Ketamine

Secondary Effects of Ziprasidone Augmentation in MDD

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

The Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis

Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies

A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia

Potential Association Between Risperidone and Cerebrovascular Events

ELSEWHERE:

FOLLOW US:

William V. Bobo, MD

Toward A Definition Of “No Meaningful Benefit” From Antidepressant Treatment

Urine Drug Screens and Youth Mortality

BMI and Remission in Depressed Patients Receiving IV Ketamine

Secondary Effects of Ziprasidone Augmentation in MDD

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients: Influence of Valproic Acid Augmentation

The Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis

Efficacy and Tolerability of Oral Paliperidone Extended-Release Tablets in the Treatment of Acute Schizophrenia: Pooled Data From Three 6-Week, Placebo-Controlled Studies

A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia

Potential Association Between Risperidone and Cerebrovascular Events

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles